Ruth Gil-Prieto

Prof. Dr. Ruth Gil-Prieto

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2009 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JAJose Luis Alvarez
Jose Luis Alvarez
RGRuth Gil-Prieto
Ruth Gil-Prieto
VHValentín Hernández-Barrera
Valentín Hernández-Barrera
AGAngel Gil
Angel Gil
Maternal health is one of the major worldwide health challenges. Currently, the unacceptably high levels of maternal mortality are a common subject in global health and development discussions. Although some countries have made remarkable progress, half of the maternal deaths in the world still take place in Sub-Saharan Africa where little or no progress has been made. There is no single simple, straightforward intervention that will significantly decrease maternal mortality alone; however, there is a consensus on the importance of a strong health system, skilled delivery attendants, and women's rights for maternal health. Our objective was to describe and determine different factors associated with the maternal mortality ratio in Sub-Saharan countries.

1 May 2015 in Medicine
Verified
Journal Article
Open access
RGRuth Gil-Prieto
Ruth Gil-Prieto
AGAlba Gonzalez-Escalada
Alba Gonzalez-Escalada
PMPatricia Marín-García
Patricia Marín-García
CGCarmen Gallardo-Pino
Carmen Gallardo-Pino
AGAngel Gil-De-Miguel
Angel Gil-De-Miguel
This epidemiological survey in Spain estimates the burden of respiratory syncytial virus (RSV) infection in children up to 5 year of age during a 15-year period (1997–2011). Observational retrospective survey was conducted by reviewing data of the National Surveillance System for Hospital Data, including >98% of Spanish hospitals. All hospitalizations related to RSV infection for children up to 5 years, reported during 1997–2011 period, were analyzed. Codes were selected by using the International Classification of Diseases 9th Clinical Modification 466.0–466.19, 480.1, and 079.6. A total of 326,175 and 286,007 hospital discharges for children up to 5 and 2 years of age were reported during the study period. The annual incidence was 1072 and 2413 patients per 100,000, respectively. The average length of hospital stay was 5.7 (standard deviation 8.2) days. Four hundred forty-six deaths were reported; of those, 403 occurred in children <2 years and 355 (80%) occurred in children <12 months of age. Hospitalization and mortality rates were significantly higher in boys and decrease significantly with age. The higher rate of hospitalization and mortality rates were found in the first year of life. Annual average cost for National Health Care System was € 47 M with a mean hospitalization cost of €2162. The average length of hospitalization and costs were significantly higher in high-risk children. RSV infections in children up to 5 year of age still pose a significant health threat in Spain, especially in the infants. The development of preventive, diagnostic, and therapeutic guidelines focused in children with comorbidities may help reduce the hospital and economic burden of the disease.

5 May 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
HBHélène Bricout
Hélène Bricout
MHMargaret Haugh
Margaret Haugh
OOOlugbenga Olatunde
Olugbenga Olatunde
RGRuth Gil-Prieto
Ruth Gil-Prieto
Reactivation of latent varicella zoster virus, partly due to age-related immunosenescence and immunosuppressive conditions, results in herpes zoster (HZ) and its associated complications. The management of the most important complication, post-herpetic neuralgia (PHN), is challenging, particularly in the elderly, and is generally unsatisfactory. No previous reviews have reported the incidence of HZ-associated mortality. We carried out a systematic literature review to identify studies and databases providing data for HZ-associated mortality in adults aged ≥50 years in Europe. We identified 12 studies: Belgium (1); France (1); Germany (1); the Netherlands (2); Portugal (1); Spain (4) and England/Wales (2) and 4 databases from Europe: France; Germany and England/Wales. The incidence was available from eight studies; it was highest in those aged ≥95 in France (19.48/100,000). In the European (WHO) database, the overall mortality ranged from 0 to >0.07/100,000. The age- and gender-specific HZ mortality rates from the other databases showed that while in younger age groups the HZ mortality rate was higher in males, in older patients the rate was much higher in women. The case fatality rate was 2 and 61/100 000 in those 45–65 and ≥65 years, respectively. A similar increase with age was seen for the hospital fatality rate; 0.6% in those 45–65 years in the UK and 7.1% in those ≥80 in Spain. Although the data were sparse and heterogeneous, HZ-associated mortality clearly increases with age. In addition, the elderly who develop HZ often have underlying diseases and are at increased risk of functional decline and loss of independence. Mortality should be taken into account in health-economics models.

1 January 2011 in Vaccine
Verified
Journal Article
Closed access
RGRuth Gil-Prieto
Ruth Gil-Prieto
LGLaura García-García
Laura García-García
AMAlejandro Alvaro Meca
Alejandro Alvaro Meca
CMCristina Méndez
Cristina Méndez
AGAna García
Ana García
ÁMÁngel Gil de Miguel
Ángel Gil de Miguel

1 January 2014 in Vaccine
Verified
Journal Article
Closed access
RGRuth Gil-Prieto
Ruth Gil-Prieto
SWStefan Walter
Stefan Walter
AGAlba Gonzalez-Escalada
Alba Gonzalez-Escalada
LGLaura Garcia-Garcia
Laura Garcia-Garcia
PMPatricia Marín-García
Patricia Marín-García
AGAngel Gil-De-Miguel
Angel Gil-De-Miguel

MHMarco Heppe-Montero
Marco Heppe-Montero
RGRuth Gil-Prieto
Ruth Gil-Prieto
JSJorge del Diego Salas
Jorge del Diego Salas
VHValentín Hernández-Barrera
Valentín Hernández-Barrera
ÁGÁngel Gil-de-Miguel
Ángel Gil-de-Miguel
Respiratory syncytial virus (RSV) infection is increasingly recognized as a cause of significant morbidity and mortality in adults. We aimed to estimate the rates of age-specific hospitalization and in-hospital mortality caused by acute lower respiratory tract infections (ALRTIs) in Spain between 2012 and 2020 and to compare the relative impact of RSV and influenza virus infection in adults. We used the discharge reports from the Minimum Basic Data Set to retrospectively analyze hospital discharge data on the basis of the ICD-9-CM and ICD-10-CM diagnosis codes. A total of 1,518,244 patients were hospitalized for ALRTIs, of whom 137,794 (9.1%) were admitted for RSV-related infections and 46,288 (3.0%) for influenza-related infections. In patients aged 60 years or older, the hospitalization rates (per 100,000 population) were estimated at 1.69 (95% CI 1.68–1.70) and 2.72 (95% CI 2.71–2.73) for RSV and influenza patients, respectively. However, in-hospital mortality rates were significantly higher among RSV patients than among influenza patients, 7.91% (95% CI 7.89–7.93) (83.0% of all RSV-related deaths) versus 6.91% (95% CI 6.89–6.93) (85.6% of all influenza-related deaths), respectively (p = 0.007). RSV-associated in-hospital mortality increases exponentially with age, posing a greater risk for older adults, particularly frail and high-risk patients.